[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339704-105":59,"doc-detail-339704-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","development-of-a-radiolabeled-cyclin-dependent-kinases-4-and-6-cdk46-inhibitor-for-brain-and-cancer-pet-imaging","Development of a Radiolabeled Cyclin-Dependent Kinases 4 and 6 (CDK4/6) Inhibitor for Brain and Cancer PET Imaging","","The synthesis, biochemical evaluation, and radiosynthesis of a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor radioligand were performed, using NT431, a newly synthesized 4-fluorobenzyl-abemaciclib. NT431 showed high potency against CDK4/6 and four cancer cell lines, with IC50 values similar to abemaciclib. A two-step one-pot radiosynthesis produced [18F]NT431 with good radiochemical yield, high purity, and high molar activity. In vitro autoradiography and dynamic PET indicated brain penetration but modest uptake, supporting limited accumulation for effective brain metastasis treatment while enabling CNS imaging and future CDK4/6 inhibitor development.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/development-of-a-radiolabeled-cyclin-dependent-kinases-4-and-6-cdk46-inhibitor-for-brain-and-cancer-pet-imaging/339704/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/development-of-a-radiolabeled-cyclin-dependent-kinases-4-and-6-cdk46-inhibitor-for-brain-and-cancer-pet-imaging/339704.png","ImageObject",300,407,{"name":92,"@type":93},"Noah","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is NT431 in this study?","Question",{"text":113,"@type":114},"NT431 is a newly synthesized 4-fluorobenzyl-abemaciclib designed as a radiolabeled CDK4/6 inhibitor radioligand for brain and cancer PET imaging.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was [18F]NT431 prepared and what were its key radiochemistry results?",{"text":118,"@type":114},"[18F]NT431 was produced via a two-step one-pot radiosynthesis, yielding good radiochemical yield, high radiochemical purity (>95%), and high molar activity.",{"name":120,"@type":111,"acceptedAnswer":121},"What did PET imaging and autoradiography show about brain penetration?",{"text":122,"@type":114},"In vitro autoradiography confirmed specific binding of [18F]NT431 to CDK4/6 in brain tissues, and dynamic PET supported that both [18F]NT431 and the parent abemaciclib crossed the BBB with modest brain uptake.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},339704,1790986170,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":41,"preview_page_count":19,"preview_urls":146},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","Article  \nDevelopment of a Radiolabeled Cyclin-Dependent Kinases 4 and 6 (CDK4/6) Inhibitor for Brain and Cancer PET Imaging  \nChun-Han Huang 1,2,3, Palwasha Khan 1,2, Sulan Xu 1,2, Jules Cohen 1,4, Georgios V. Georgakis 1,5 and Nashaat Turkman 1,2,3, *  \nCitation: Huang, C.-H.; Khan, P.; Xu, S.; Cohen, J.; Georgakis, G.V.; Turkman, N. Development of a Radiolabeled Cyclin-Dependent Kinases 4 and 6 (CDK4/6) Inhibitor for Brain and Cancer PET Imaging. Int. J. Mol. Sci. 2024, 25, 6870. [https://](https://)[ ](https://)[doi.org/10.3390/ijms25136870](doi.org/10.3390/ijms25136870)  \nAcademic Editor: Giorgio Treglia  \nReceived: 13 May 2024  \nRevised: 18 June 2024  \nAccepted: 19 June 2024  \nPublished: 22 June 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Stony Brook Cancer Center, Stony Brook, Long Island, NY 11794, USA  \n2 Department of Radiology, School of Medicine, Stony Brook University, Long Island, NY 11794, USA  \n3 Department of Biomedical Engineering, Stony Brook University, Long Island, NY 11794, USA  \n4 Department of Medicine, School of Medicine, Stony Brook University, Long Island, NY 11794, USA  \n5 Department of Surgery, School of Medicine, Stony Brook University, Long Island, NY 11794, USA  \n* [Correspondence: nashaat.turkman@stonybrookmedicine.edu](Correspondence: nashaat.turkman@stonybrookmedicine.edu); Tel.: +1-631-444-7938  \nAbstract: The synthesis, biochemical evaluation and radiosynthesis of a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor and radioligand was performed. NT431, a newly synthesized 4-fluorobenzyl-abemaciclib, exhibited high potency to CDK4/6 and against four cancer cell lines with IC50 similar to that of the parent abemaciclib. We performed a two-step one-pot radiosynthesis to produce [18F]NT431 with good radiochemical yield (9 .6 ± 3%, n = 3, decay uncorrected), high radiochemical purity (>95%), and high molar activity (>370 GBq/µmol (>10.0 Ci/µmol) . In vitro autoradiography confirmed the specific binding of [18F]NT431 to CDK4/6 in brain tissues. Dynamic PET imaging supports that both [18F]NT431 and the parent abemaciclib crossed the BBB albeit with modest brain uptake. Therefore, we conclude that it is unlikely that NT431 or abemaciclib (FDA approved drug) can accumulate in the brain in sufficient concentrations to be potentially effective against breast cancer brain metastases or brain cancers. However, despite the modest BBB penetration,[18F]NT431 represents an important step towards the development and evaluation of a new generation of CDK4/6 inhibitors with superior BBB penetration for the treatment and visualization of CDK4/6 positive tumors in the CNS. Also,[18F]NT431 may have potential application in peripheral tumors such as breast cancer and other CDK4/6 positive tumors.  \nKeywords: CDK4/6; PET; abemaciclib; BBB; CNS  \n1. Introduction  \nCyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors suppress the dysregulation of the cell cycle by blocking the aberrantly accelerated cell cycle transition from the G1 to S phase [1,2] . This transition is regulated by a complex consisting of CDK4/6 and cyclin D, which phosphorylates retinoblastoma-associated proteins (pRb) and introduces E2F release [3–5] . CDK4/6 proteins have been reported to be overexpressed in a significant number of cancers such as head and neck cancer [6], non–small cell lung cancer [7], melanoma [8–10], and glioblastoma [11] . High levels of CDK4/6 overexpression have been observed in patients with luminal (i.e., estrogen receptor (ER)–positive) breast cancer, the most common subtype, representing approximately 75% of all breast cancers [12,13] . Moreover, overexpression of CDK4/6 appears to be an early step","cbCaije6yn1APRWK","https://ap.wps.com/l/cbCaije6yn1APRWK","pdf",2391209,12,"English","# Abstract\n# 1. Introduction\n## CDK4/6 inhibitors and cell-cycle regulation\n## Clinical context and FDA-approved inhibitors\n## Limitations for CNS tumors and need for PET probes","[{\"question\":\"What is NT431 in this study?\",\"answer\":\"NT431 is a newly synthesized 4-fluorobenzyl-abemaciclib designed as a radiolabeled CDK4/6 inhibitor radioligand for brain and cancer PET imaging.\"},{\"question\":\"How was [18F]NT431 prepared and what were its key radiochemistry results?\",\"answer\":\"[18F]NT431 was produced via a two-step one-pot radiosynthesis, yielding good radiochemical yield, high radiochemical purity (\\u003e95%), and high molar activity.\"},{\"question\":\"What did PET imaging and autoradiography show about brain penetration?\",\"answer\":\"In vitro autoradiography confirmed specific binding of [18F]NT431 to CDK4/6 in brain tissues, and dynamic PET supported that both [18F]NT431 and the parent abemaciclib crossed the BBB with modest brain uptake.\"}]","Development of a Radiolabeled Cyclin-Dependent Kinases 4 and 6 (CDK4/6) Inhibitor for Brain and Cancer PET Imaging | PDF",1790031704,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7de76d6f64cc82a589004d0bb38a3013.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7775ef4e2597cb149e77d2bf407cfafc.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4dfbe96ab7d83f4119edd95ddf233b50.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e9cfebd8c2be618f8d2857ff549d0d3e.webp",980,1385]